Kymera Therapeutics

Development and Performance of Pharmacodynamic Assays to Demonstrate Proof-of-Mechanism for IRAK4 Degraders in a Phase1 Study

Read more

The Phase 1 Healthy Volunteer Clinical Trial of KT-474

Read more

Utilizing degraders to Modulate B & T Cell Targets for Autoimmune Diseases

Read more

Discovery and characterization of IRAKIMiDs: degraders targeting both IRAK4 and IMiD substrates for oncology indications

Read more

Discovery and targeted mass spectrometry-based proteomics: Enabling technologies advancing IRAK4 protein degrader along the drug discovery pipeline into the clinic

Read more

Kinetics of IRAK4 Degradation and Impact on Functional Response in Circulating Immune Cells and Skin Cell Subsets

Read more

Selective IRAK4 Degradation, Not Kinase Inhibition, Blocks TLR-activated NF-kB and p38 Signaling Leading to broad Cytokine Inhibition

Read more

European Protein Degradation Congress, September 21st-23rd, 2021

Read more

The First Proof-of-Mechanism in a Randomized, Placebo-controlled Study in Targeted Protein Degradation

Read more

16th Annual International Conference on Malignant Lymphoma (ICML) Virtual Meeting, June 18 – 22, 2021

Read more